Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children

BACKGROUND: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirima, Sodiomon B., Tiono, Alfred B., Ouédraogo, Alphonse, Diarra, Amidou, Ouédraogo, André Lin, Yaro, Jean Baptiste, Ouédraogo, Espérance, Gansané, Adama, Bougouma, Edith C., Konaté, Amadou T., Kaboré, Youssouf, Traoré, Abdoulaye, Roma, Chilengi, Soulama, Issiaka, Luty, Adrian J. F., Cousens, Simon, Nébié, Issa
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764341/
https://www.ncbi.nlm.nih.gov/pubmed/19855847
http://dx.doi.org/10.1371/journal.pone.0007549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764341/
https://www.ncbi.nlm.nih.gov/pubmed/19855847
http://dx.doi.org/10.1371/journal.pone.0007549

Ejemplares similares